Eovist
Loading...Eovist Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
EOVIST is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.
History
There is currently no drug history available for this drug.
Other Information
EOVIST (gadoxetate disodium) is a paramagnetic contrast agent administered for MRI. EOVIST is provided as a sterile, clear, colorless to pale yellow aqueous solution for intravenous injection.
EOVIST contains the active pharmaceutical ingredient, gadoxetate disodium (Gd‑EOB‑DTPA). The chemical name for gadoxetate disodium is (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid, gadolinium complex, disodium salt. Gadoxetate disodium has a molecular weight of 725.72 and an empirical formula of GdC23H28N3O11Na2. The structural formula of gadoxetate disodium in aqueous solution is:
Each mL of EOVIST contains 181.43 mg of gadoxetate disodium (equivalent to 0.25 mmol/mL gadoxetate disodium) and the excipients caloxetate trisodium, trometamol, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and water for injection. EOVIST contains no antimicrobial preservative.
Pertinent physiochemical properties of EOVIST are provided in Table 2.
| Osmolality at 37°C (Osm/kg H2O) |
0.688 |
| Viscosity at 37°C (cP) |
1.19 |
| Density at 37°C (g/mL) |
1.088 |
| pH |
6.8-8 |
Sources
Eovist Manufacturers
-
Bayer Healthcare Pharmaceuticals Inc.
![Eovist (Gadoxetate Disodium) Injection, Solution [Bayer Healthcare Pharmaceuticals Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Eovist | Bayer Healthcare Pharmaceuticals Inc.
2.1 Recommended DoseThe recommended dose of EOVIST is 0.1 mL/kg body weight (0.025 mmol/kg body weight).
2.2 Drug Handling and Administration • Use sterile technique when preparing and administering EOVIST • Visually inspect EOVIST, supplied in a single-use vial, for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or if particulate matter is present • Use EOVIST immediately after obtaining appropriate dose from vial. The rubber stopper should never be pierced more than once. Discard any unused portion of an EOVIST vial • Administer EOVIST undiluted as an intravenous bolus injection at a flow rate of approximately 2 mL/second • Do not mix EOVIST with other medications and do not administer EOVIST in the same intravenous line simultaneously with other medications • Flush the intravenous cannula with a normal saline solution after EOVIST injection • Imaging can commence immediately following EOVIST administration 2.3 Imaging • Liver lesions are detected and characterized with pre-contrast MRI and EOVIST MRI obtained during dynamic and hepatocyte imaging phases. Perform a pre-contrast MRI, inject EOVIST and begin dynamic imaging approximately 15–25 seconds after completion of the injection. Dynamic imaging consists of the arterial, the porto-venous (approximately 60 seconds post-injection), and the blood equilibrium (approximately 120 seconds) phases. • Begin the hepatocyte imaging phase approximately 20 minutes post-injection. Hepatocyte phase imaging may be performed up to 120 minutes post-injection. • Elevated intrinsic levels of bilirubin (>3 mg/dL) or ferritin can reduce the hepatic contrast effect of EOVIST. Perform MR imaging no later than 60 minutes following EOVIST administration to patients with these laboratory abnormalities, including patients who have elevated ferritin levels due to hemodialysis [see Warnings and Precautions (5.6) and Use in Specific Populations (8.6, 8.7)]. • Lesions with no or minimal hepatocyte function (cysts, metastases, and the majority of hepatocellular carcinomas) generally will not accumulate EOVIST. Well-differentiated hepatocellular carcinoma may contain functioning hepatocytes and can show some enhancement in the hepatocyte imaging phase. Additional clinical information is therefore needed to support a diagnosis of hepatocellular carcinoma.
Login To Your Free Account